Company Overview and News

 
The Food Revolution Group Ltd to produce orange juice for ALDI

2016-11-09 proactiveinvestors.com.au
The food and beverage processing company manufactures a range of juices, fibres, infused fruits and fruit waters that are sold as branded products or ingredients to customers. The Food Revolution Group’s share price was last trading at $0.115, up 9.52% intraday. The latest orange juice product will be available for sale in ALDI stores in Victoria, South Australia and Western Australia, starting this month.

 
The Food Revolution Group Ltd launching products in Coles and Woolworths

2016-10-07 proactiveinvestors.com.au
The Food Revolution Group Ltd (ASX:FOD) will launch new products to extend its The Juice Lab ranges at Coles and Woolworths this month. Food Revolution is a food and beverage processing company with operations in Victoria, it manufactures juices, fibres, infused fruits and fruit waters. The new products include reduced-sugar juices and larger take-home packs. New products are aimed at continuing to drive earnings for the company, which totalled $933,000 EBITDA for FY2016.

 
The Food Revolution Group Ltd launching products in Coles and Woolworths

2016-10-06 proactiveinvestors.com.au
The Food Revolution Group Ltd (ASX:FOD) formerly Crest Minerals is an Australian public company that operates state-of-the-art fruit and vegetable processing facilities in Victoria and New Zealand, manufacturing a range of high quality juices, fibres, infused fruits and waters and bio-actives.

 
Food Revolution’s pull of Gravity

2016-08-08 perthnow.com.au
HEALTH drink maker The Food Revolution Group will lease part of its plant at Mill Park, in Melbourne’s north, to a Singaporean company.

 
Juice maker expands at home, looks abroad

2016-04-04 news.theage.com.au
JavaScript disabled. Please enable JavaScript to use My News, My Clippings, My Comments and user settings.

 
Juice maker expands at home, looks abroad

2016-04-04 news.smh.com.au
JavaScript disabled. Please enable JavaScript to use My News, My Clippings, My Comments and user settings.

 
Food and juice maker to expand footprint

2016-04-04 news.theage.com.au
JavaScript disabled. Please enable JavaScript to use My News, My Clippings, My Comments and user settings.

 
Food and juice maker to expand footprint

2016-04-04 news.smh.com.au
JavaScript disabled. Please enable JavaScript to use My News, My Clippings, My Comments and user settings.

 
Healthy start for The Food Revolution

2016-02-19 news.theage.com.au
"Functional food" maker The Food Revolution has made a solid debut to trading on the Australian share market.

 
Healthy start for The Food Revolution

2016-02-19 news.smh.com.au
"Functional food" maker The Food Revolution has made a solid debut to trading on the Australian share market.

 
Health start for The Food Revolution

2016-02-19 news.theage.com.au
"Functional food" maker The Food Revolution has made a solid debut to trading on the Australian share market.

 
Health start for The Food Revolution

2016-02-19 news.smh.com.au
"Functional food" maker The Food Revolution has made a solid debut to trading on the Australian share market.

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...